[Familial recurrent bilateral panuveitis: efficiency of alpha interferon]

Area of Science:

• Ophthalmology
• Immunology
• Medical Therapeutics

Background:

• Severe recurrent uveitis lacks a definitive treatment consensus.
• Current immunosuppressive therapies exhibit variable efficacy and significant adverse effects.
• Idiopathic panuveitis presents a therapeutic challenge, often requiring long-term management.

Observation:

• Two brothers with severe, recurrent idiopathic panuveitis, refractory to conventional treatments like corticosteroids and cyclosporine, were treated with alpha interferon.
• Both patients demonstrated marked improvement in visual acuity.
• The older brother experienced no recurrences during treatment and a one-year follow-up, while the younger brother showed stabilization of ocular lesions over a nine-month follow-up.

Findings:

• Alpha interferon therapy demonstrated significant efficacy in managing severe idiopathic panuveitis.
• The treatment was well-tolerated, with no reported ophthalmologic adverse effects.
• The study suggests alpha interferon as a viable therapeutic option for severe, refractory cases of idiopathic panuveitis.

Implications:

• Alpha interferon represents a potentially effective and safe treatment for severe idiopathic panuveitis.
• Further research is warranted to establish optimal dosage and treatment duration for alpha interferon therapy.
• This case series may inform future clinical trials investigating alpha interferon for uveitis management.